All Oncology News

Pegcetacoplan treatment was associated with hemoglobin stabilization and normalization, as well as a superior change from baseline in hemoglobin levels, which showed a meaningful correction of anemia, in patients with complement inhibitor–naïve paroxysmal nocturnal hemoglobinuria.

First-line pembrolizumab monotherapy continued to elicit an overall survival benefit and durable tumor response vs standard-of-care platinum-based chemotherapy in Chinese patients with untreated PD-L1–positive, advanced or metastatic non–small cell lung cancer without sensitizing EGFR or ALK mutations.

Temferon, genetically modified Tie2-expressing monocytes targeting interferona2, showed the potential to activate the immune system and reprogram the tumor microenvironment in patients with glioblastoma.

Nivolumab in combination with a PD-L1/IDO peptide vaccine displayed encouraging efficacy and survival results among patients with metastatic melanoma.

Sara A. Hurvitz, MD, medical oncologist and medical director at the Jonsson Comprehensive Cancer Center Clinical Research Unit, discussed pivotal findings in the HER2-positive treatment landscape that possess the potential to change practice.

Avelumab is now a treatment option for patients with urothelial cancer in the United Kingdom following a recommendation from the National Institute for Health and Care Excellence issued Thursday, April 7, 2022.1

Researchers at the Yale Cancer Biology Institute have clarified the role of a recurring cancer-associated tumor mutation in glioblastoma multiforme, the most common and most aggressive type of malignant brain tumor.

Zanubrutinib monotherapy continues to demonstrate durable responses with an acceptable toxicity profile in patients with relapsed or refractory mantle cell lymphoma.

Prostate cancer is the most common cancer in men and the second-leading cause of cancer-related deaths in men in the US.

The China National Medical Products Administration’s Center for Drug Evaluation has granted a breakthrough therapy designation to relmacabtagene autoleucel for use in the treatment of patients with mantle cell lymphoma.

The use of trilaciclib prior to chemotherapy resulted in a 50% reduction in the percent of patients with extensive-stage small cell lung cancer who had grade 3 or higher myelosuppressive hematologic adverse effects in at least 1 blood cell lineage.

Women of all races and ethnicities who were referred to a colposcopy clinic for cervical cancer screening following an abnormal Pap smear during the COVID-19 pandemic had a higher likelihood of not adhering to their appointment compared with appointment data collected prior to the pandemic.

Checkpoint inhibitors prior to allogeneic hematopoietic cell transplant improved progression-free survival and relapse incidence in patients with Hodgkin lymphoma, but the treatment did not improve non-relapse mortality or overall survival.

Justin W. Taylor, MD, discusses the significance of BTK inhibition in the treatment of patients with CLL, the genomic analyses conducted in those enrolled to BRUIN who received pirtobrutinib, and the significance of the data yielded from this research.

Researchers at the Icahn School of Medicine at Mount Sinai describe a troubling increase in early-onset colorectal cancer and precancerous polyps, based on a large, nationally representative study of patients under age 50 who underwent colonoscopy.

Specialization in oncology research affords investigators the opportunity to dive into tumor biology and uncover unique approaches to care.

Venetoclax consolidation following first-line treatment with venetoclax and obinutuzumab did not reduce loss of minimal residual disease response vs MRD-guided venetoclax consolidation in previously untreated patients with chronic lymphocytic leukemia.

The combination of the oncolytic vaccine vusolimogene oderparepvec and nivolumab continued to drive encouraging responses with acceptable tolerability in patients with melanoma and other skin cancers.

Marketing authorization applications seeking the approval of tislelizumab in patients with advanced or metastatic esophageal squamous cell carcinoma following previous systemic chemotherapy and in select patients with non–small cell lung cancer have been submitted to the European Medicines Agency.

The FDA has provided positive feedback regarding Iovance Biotherapeutics, Inc.’s proposed matrix of potency assays for an upcoming biologics license application seeking the approval of lifileucel in the treatment of patients with metastatic melanoma.

Selecting the optimal frontline treatment regimen for patients with unresectable metastatic colorectal cancer requires careful consideration of multiple patient and treatment characteristics.

The National Cancer Institute recently awarded Yale Cancer Center and Yale School of Public Health a new U01 cooperative agreement grant to support research into the impact of diet and exercise for women with ovarian cancer.

Walter J. Curran Jr, MD, always had the potential to be an overachiever, but his sense of discipline turned that potential into reality.

Ann S. LaCasce, MD, MMSc, discusses updates in lymphoma, myelofibrosis, and chronic lymphocytic leukemia.

The European Commission has approved the dual immunotherapy combination of nivolumab and ipilimumab for use in the frontline treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma who had a PD-L1 expression of 1% or higher on tumor cells.

The European Commission has granted marketing authorization to the CD19-directed CAR T-cell therapy lisocabtagene maraleucel for use in adult patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B following 2 or more lines of systemic treatment.

The European Commission has approved nivolumab in combination with fluoropyrimidine- and platinum-based chemotherapy for the frontline treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma with a PD-L1 expression of 1% or higher on tumor cells.

Research led by UT Southwestern scientists suggests that an investigational drug could restore the ability of some non–small cell lung cancers to respond to an immune checkpoint blockade, a therapy that harnesses the immune system to fight malignant tumors.

The European Commission has approved nivolumab for use in the adjuvant treatment of adult patients with muscle-invasive urothelial carcinoma and a PD-L1 expression of 1% or higher on tumor cells, who are at a high risk of recurrence following radical resection.

Patients who develop post–essential thrombocythemia myelofibrosis or post–polycythemia vera myelofibrosis, which are associated with significant symptom burden and bone marrow failure, have limited therapies available for effective treatment.